Identification of a class of novel tubulin inhibitors

Journal of Medicinal Chemistry

Volumn 55, Issue 7, 2012, Pages 3425-3435

  Yi, Xin ^a   Zhong, Bo ^a   Smith, Kerri M ^a   Geldenhuys, Werner J ^b   Feng, Ye ^a   Pink, John J ^c   Dowlati, Afshin ^c   Xu, Yan ^a   Zhou, Aimin ^a   Su, Bin ^a  

^a CLEVELAND STATE UNIVERSITY   (United States)

^b NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLCHICINE; ERIBULIN; HEAT SHOCK PROTEIN 27; IXABEPILONE; N [2 [(4 HYDROXYPHENYL)AMINO] 3 PYRIDINYL] 4 METHOXYBENZENESULFONAMIDE; PACLITAXEL; TUBULIN; VINBLASTINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG IDENTIFICATION; DRUG STRUCTURE; DRUG TARGETING; PROTEIN PHOSPHORYLATION; PROTEIN POLYMERIZATION;

ANTINEOPLASTIC AGENTS; BENZODIOXOLES; BIOTINYLATION; CELL LINE, TUMOR; HSP27 HEAT-SHOCK PROTEINS; HUMANS; MODELS, MOLECULAR; MOLECULAR PROBES; PHOSPHORYLATION; PROTEIN BINDING; PROTEOMICS; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES; TUBULIN; TUBULIN MODULATORS;

EID: 84859798098     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm300100d     Document Type: Article

References (46)

1. Heald, R.; Nogales, E. Microtubule dynamics J. Cell Sci. 2002, 115, 3-4
2. Rowinsky, E. K. Paclitaxel pharmacology and other tumor types Semin. Oncol. 1997, 24, S19-1-S19-12
3. Kuppens, I. E. Current state of the art of new tubulin inhibitors in the clinic Curr. Clin. Pharmacol. 2006, 1, 57-70
4. Orr, G. A.; Verdier-Pinard, P.; McDaid, H.; Horwitz, S. B. Mechanisms of Taxol resistance related to microtubules Oncogene 2003, 22, 7280-7295
5. Perez, E. A. Microtubule inhibitors: differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance Mol. Cancer Ther. 2009, 8, 2086-2095
6. Perez, E. A. Impact, mechanisms, and novel chemotherapy strategies for overcoming resistance to anthracyclines and taxanes in metastatic breast cancer Breast Cancer Res. Treat. 2009, 114, 195-201
7. Carlson, K.; Ocean, A. J. Peripheral neuropathy with microtubule- targeting agents: occurrence and management approach Clin. Breast Cancer. 2011, 11, 73-81
8. Swain, S. M.; Arezzo, J. C. Neuropathy associated with microtubule inhibitors: diagnosis, incidence, and management Clin. Adv. Hematol. Oncol. 2008, 6, 455-467
9. Wozniak, K. M.; Nomoto, K.; Lapidus, R. G.; Wu, Y.; Carozzi, V.; Cavaletti, G.; Hayakawa, K.; Hosokawa, S.; Towle, M. J.; Littlefield, B. A.; Slusher, B. S. Comparison of neuropathy-inducing effects of eribulin mesylate, paclitaxel, and ixabepilone in mice Cancer Res. 2011, 71, 3952-3962
10. Britten, C. D.; Baker, S. D.; Denis, L. J.; Johnson, T.; Drengler, R.; Siu, L. L.; Duchin, K.; Kuhn, J.; Rowinsky, E. K. Oral paclitaxel and concurrent cyclosporin A: targeting clinically relevant systemic exposure to paclitaxel Clin. Cancer Res. 2000, 6, 3459-3468
11. Lee, J. J.; Kelly, W. K. Epothilones: tubulin polymerization as a novel target for prostate cancer therapy Nat. Clin. Pract. Oncol. 2009, 6, 85-92
12. Bollag, D. M.; McQueney, P. A.; Zhu, J.; Hensens, O.; Koupal, L.; Liesch, J.; Goetz, M.; Lazarides, E.; Woods, C. M. Epothilones, a new class of microtubule-stabilizing agents with a Taxol-like mechanism of action Cancer Res. 1995, 55, 2325-2333
13. Bai, R.; Nguyen, T. L.; Burnett, J. C.; Atasoylu, O.; Munro, M. H.; Pettit, G. R.; Smith, A. B., 3rd; Gussio, R.; Hamel, E. Interactions of halichondrin B and eribulin with tubulin J. Chem. Inf. Model. 2011, 51, 1393-1404
14. Bai, R. L.; Paull, K. D.; Herald, C. L.; Malspeis, L.; Pettit, G. R.; Hamel, E. Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data J. Biol. Chem. 1991, 266, 15882-15889
15. Horwitz, S. B.; Cohen, D.; Rao, S.; Ringel, I.; Shen, H. J.; Yang, C. P. Taxol: mechanisms of action and resistance J. Natl. Cancer. Inst. Monogr. 1993, 15, 55-61
16. Bacher, G.; Nickel, B.; Emig, P.; Vanhoefer, U.; Seeber, S.; Shandra, A.; Klenner, T.; Beckers, T. D-24851, a novel synthetic microtubule inhibitor, exerts curative antitumoral activity in vivo, shows efficacy toward multidrug-resistant tumor cells, and lacks neurotoxicity Cancer Res. 2001, 61, 392-399
17. Beckers, T.; Reissmann, T.; Schmidt, M.; Burger, A. M.; Fiebig, H. H.; Vanhoefer, U.; Pongratz, H.; Hufsky, H.; Hockemeyer, J.; Frieser, M.; Mahboobi, S. 2-Aroylindoles, a novel class of potent, orally active small molecule tubulin inhibitors Cancer Res. 2002, 62, 3113-3119
18. Hande, K. R.; Hagey, A.; Berlin, J.; Cai, Y.; Meek, K.; Kobayashi, H.; Lockhart, A. C.; Medina, D.; Sosman, J.; Gordon, G. B.; Rothenberg, M. L. The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 study Clin. Cancer Res. 2006, 12, 2834-2840
19. Su, B.; Darby, M. V.; Brueggemeier, R. W. Synthesis and biological evaluation of novel sulfonanilide compounds as antiproliferative agents for breast cancer J. Comb. Chem. 2008, 10, 475-483
20. Zhong, B.; Cai, X.; Chennamaneni, S.; Yi, X.; Liu, L.; Pink, J. J.; Dowlati, A.; Xu, Y.; Zhou, A.; Su, B. From COX-2 inhibitor nimesulide to potent anti-cancer agent: synthesis, in vitro, in vivo and pharmacokinetic evaluation Eur. J. Med. Chem. 2012, 47, 432-444
21. Baoping, Y.; Guoyong, H.; Jieping, Y.; Zongxue, R.; Hesheng, L. Cyclooxygenase-2 inhibitor nimesulide suppresses telomerase activity by blocking Akt/PKB activation in gastric cancer cell line Dig. Dis. Sci. 2004, 49, 948-953
22. Elder, D. J.; Halton, D. E.; Hague, A.; Paraskeva, C. Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: independence from COX-2 protein expression Clin. Cancer Res. 1997, 3, 1679-1683
23. Hanif, R.; Pittas, A.; Feng, Y.; Koutsos, M. I.; Qiao, L.; Staiano-Coico, L.; Shiff, S. I.; Rigas, B. Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway Biochem. Pharmacol. 1996, 52, 237-245
24. Johnson, A. J.; song, X.; Hsu, A.; Chen, C. Apoptosis signaling pathways mediated by cyclooxygenase-2 inhibitors in prostate cancer cells Adv. Enzyme Regul. 2001, 41, 221-235
25. Pan, Y.; Zhang, J. S.; Gazi, M. H.; Young, C. Y. The cyclooxygenase 2-specific nonsteroidal anti-inflammatory drugs celecoxib and nimesulide inhibit androgen receptor activity via induction of c-Jun in prostate cancer cells Cancer Epidemiol., Biomarkers Prev. 2003, 12, 769-774
26. Shiff, S. J.; Koutsos, M. I.; Qiao, L.; Rigas, B. Nonsteroidal antiinflammatory drugs inhibit the proliferation of colon adenocarcinoma cells: effects on cell cycle and apoptosis Exp. Cell Res. 1996, 222, 179-188
27. Alberts, D. S.; Hixson, L.; Ahnen, D.; Bogert, C.; Einspahr, J.; Paranka, N.; Brendel, K.; Gross, P. H.; Pamukcu, R.; Burt, R. W. Do NSAIDs exert their colon cancer chemoprevention activities through the inhibition of mucosal prostaglandin synthetase? J. Cell. Biochem. Suppl. 1995, 22, 18-23
28. Julemont, F.; de Leval, X.; Michaux, C.; Damas, J.; Charlier, C.; Durant, F.; Pirotte, B.; Dogne, J. M. Spectral and crystallographic study of pyridinic analogues of nimesulide: determination of the active form of methanesulfonamides as COX-2 selective inhibitors J. Med. Chem. 2002, 45, 5182-5185
29. Su, B.; Diaz-Cruz, E. S.; Landini, S.; Brueggemeier, R. W. Novel sulfonanilide analogues suppress aromatase expression and activity in breast cancer cells independent of COX-2 inhibition J. Med. Chem. 2006, 49, 1413-1419
30. Boelsterli, U. A.; Ho, H. K.; Zhou, S.; Leow, K. Y. Bioactivation and hepatotoxicity of nitroaromatic drugs Curr. Drug Metab. 2006, 7, 715-727
31. Zhong, B.; Cai, X.; Yi, X.; Zhou, A.; Chen, S.; Su, B. In vitro and in vivo effects of a cyclooxygenase-2 inhibitor nimesulide analog JCC76 in aromatase inhibitors-insensitive breast cancer cells J. Steroid Biochem. Mol. Biol. 2011, 126, 10-18
32. Chen, B.; Su, B.; Chen, S. A COX-2 inhibitor nimesulide analog selectively induces apoptosis in Her2 overexpressing breast cancer cells via cytochrome c dependent mechanisms Biochem. Pharmacol. 2009, 77, 1787-1794
33. Rix, U.; Superti-Furga, G. Target profiling of small molecules by chemical proteomics Nat. Chem. Biol. 2009, 5, 616-624
34. Zhong, B.; Lama, R.; Smith, K. M.; Xu, Y.; Su, B. Design and synthesis of a biotinylated probe of COX-2 inhibitor nimesulide analog JCC76 Bioorg. Med. Chem. Lett. 2011, 21, 5324-5327
35. Sherman, M.; Multhoff, G. Heat shock proteins in cancer Ann. N.Y. Acad. Sci. 2007, 1113, 192-201
36. Hino, M.; Kurogi, K.; Okubo, M. A.; Murata-Hori, M.; Hosoya, H. Small heat shock protein 27 (HSP27) associates with tubulin/microtubules in HeLa cells Biochem. Biophys. Res. Commun. 2000, 271, 164-169
37. Rowinsky, E. K. Current developments in antitumor antibiotics, epipodophyllotoxins, and vinca alkaloids Curr. Opin. Oncol. 1991, 3, 1060-1069
38. Nettles, J. H.; Li, H.; Cornett, B.; Krahn, J. M.; Snyder, J. P.; Downing, K. H. The binding mode of epothilone A on alpha,beta-tubulin by electron crystallography Science 2004, 305, 866-869
39. Bruey, J. M.; Ducasse, C.; Bonniaud, P.; Ravagnan, L.; Susin, S. A.; Diaz-Latoud, C.; Gurbuxani, S.; Arrigo, A. P.; Kroemer, G.; Solary, E.; Garrido, C. Hsp27 negatively regulates cell death by interacting with cytochrome c Nat. Cell Biol. 2000, 2, 645-652
40. Bruey, J. M.; Paul, C.; Fromentin, A.; Hilpert, S.; Arrigo, A. P.; Solary, E.; Garrido, C. Differential regulation of HSP27 oligomerization in tumor cells grown in vitro and in vivo Oncogene 2000, 19, 4855-4863
41. Langer, R.; Ott, K.; Specht, K.; Becker, K.; Lordick, F.; Burian, M.; Herrmann, K.; Schrattenholz, A.; Cahill, M. A.; Schwaiger, M.; Hofler, H.; Wester, H. J. Protein expression profiling in esophageal adenocarcinoma patients indicates association of heat-shock protein 27 expression and chemotherapy response Clin. Cancer Res. 2008, 14, 8279-8287
42. Sun, Y.; MacRae, T. H. The small heat shock proteins and their role in human disease FEBS J. 2005, 272, 2613-2627
43. Casado, P.; Zuazua-Villar, P.; Prado, M. A.; Valle, E. D.; Iglesias, J. M.; Martinez-Campa, C.; Lazo, P. S.; Ramos, S. Characterization of HSP27 phosphorylation induced by microtubule interfering agents: implication of p38 signalling pathway Arch. Biochem. Biophys. 2007, 461, 123-129
44. Shin, K. D.; Lee, M. Y.; Shin, D. S.; Lee, S.; Son, K. H.; Koh, S.; Paik, Y. K.; Kwon, B. M.; Han, D. C. Blocking tumor cell migration and invasion with biphenyl isoxazole derivative KRIBB3, a synthetic molecule that inhibits Hsp27 phosphorylation J. Biol. Chem. 2005, 280, 41439-41448
45. Ravelli, R. B.; Gigant, B.; Curmi, P. A.; Jourdain, I.; Lachkar, S.; Sobel, A.; Knossow, M. Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain Nature 2004, 428, 198-202
46. Su, B.; Tian, R.; Darby, M. V.; Brueggemeier, R. W. Novel sulfonanilide analogs decrease aromatase activity in breast cancer cells: synthesis, biological evaluation, and ligand-based pharmacophore identification J. Med. Chem. 2008, 51, 1126-1135